The rationale for combining CDK4/6 inhibitors with radiation is in part based on data supporting the importance of cyclin D1 in radio-sensitizing prostate cancers and the possibility that CDK4/6 inhibition may potentiate the effects of radiation [83,84]. This evidence concerns the gene CDK4 and prostate carcinoma.